Лечение антифосфолипидного синдрома: современные стандарты
УДК 616-005.6:616.151.5:612.115.3
Аннотация
В обзоре приведены сведения об этиологии и патогенезе антифосфолипидного синдрома (АФС), генетической предрасположенности к его развитию. Представлены последние международные критерии диагностики AФC и его варианты. Данный синдром в зависимости от локализации тромбоза может поражать несколько систем органов, поэтому проблема AФC в наше время является мультидисциплинарной. Клинические проявления АФС достаточно общие (тромбозы различной локализации), поэтому диагноз может быть верифицирован только при наличии антифосфолипидных антител. Рассмотрена дифференциальная диагностика АФС.
Литература
- Антифосфолипидный синдром [Под ред.
Е. Л. Насонова ]. — М.: Литтера, 2004. — 424 с. - Miyakis S., Lockshin M., Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) // J. Thromb. Haemost. — 2006. — Vol. 4. — Р. 295–306.
- Решетняк
Т. М. Антифосфолипидный синдром // В кн.: Клинические лекции по ревматологии [Под ред.В. В. Бадокина ]. — М.:ГЭОТАР-Медиа , 2011. — С. 377–406. - Решетняк
Т. М. Антифосфолипидный синдром: диагностика и клинические проявления (лекция) //Научно-практическая ревматология. — 2014. — Т. 52, № 1. — С. 56–71. - Antiphospholipid Syndrome: Insights and Highlights from the 13th International Congress on Antiphospholipid Antibodies [Еds. D. Erkan,
S. S. Pierangeli ]. — New York: © Springer Science + Business Media, 2012 (doi: 10.1007/978- 1-4614-3194-7_17 ). - Pengo
v. , Tripodi A., Reber G. et al. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardization committee of the international society on thrombosis and haemostasis. Update of the guidelines for lupus anticoagulant detection // J. Thromb. Haemost. — 2009. — Vol. 7, № 10. — P. 1737–1740. - Pengo
v. , Ruffatti A., Legnani C. et al. Clinical course ofhigh-risk patients diagnosed with antiphospholipid syndrome // J. Thromb. Haemost. — 2010. — Vol. 8, № 2. — Р. 237–242. - Pengo
v. Classification criteria of thrombotic APS // Proceedings of the 9th Meeting of the European Forum on Antiphospholipid Antibodies. Medycynapraktyczna. Final program and lectures. — Krakow, Poland. — 2013, May 16–18. — Р. 16–17. - Proven A., Bartlett R. P., Moder K. G. et al. Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodies // Mayo Clin. Proc. — 2004. — Vol. 79, № 4. — Р. 467–475.
- Guyatt G. H., Cook D. J., Jaeschke R. et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians
Evidence-Based Clinical Practice Guidelines (8th еd.) // Chest. — 2008. — Vol. 133 (Suppl 6). —123S-131S . Ruiz-Irastorza G., Hunt B. J., Khamashta M. A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies // Arthritis Rheum. — 2007. — Vol. 57, № 8. — Р. 1487–1495.Ruiz-Irastorza G., Cuadrado M.,Ruiz-Arruza I. et al.Evidence-based recommendations for the prevention andlong-term management of thrombosis in antiphospholipidantibody-positive patients: report of a task force at the 13th international congress on antiphospholipid antibodies // Lupus. — 2011. — Vol. 20. — Р. 206–218.- Crowther M. A., Ginsberg J. S., Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome // N. Engl. J. Med. — 2003. — Vol. 349. — Р. 1133–1138.
- Finazzi G., Marchioli R., Brancaccio
v. et al. A randomized clinical trial ofhigh-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS) // J. Thromb. Haemost. — 2005. — Vol. 3. — Р. 848–853. - Torn M., van der Meer F. J., Rosendaal
F. R. Lowering the intensity of oral anticoagulant therapy: effects on the risk of hemorrhage and thromboembolism // Arch. Intern. Med. — 2004. — Vol. 164. — Р. 668–673. - Khamashta M. A., Cuadrado M. J., Mujic F. et al. The management of thrombosis in the
antiphospholipid-antibody syndrome // N. Engl. J. Med. — 1995. — Vol. 332, № 15. — Р. 993–997. - Levine S. R., Brey R. L., Tilley B. C. et al. Antiphospholipid antibodies and subsequent
thrombo-occlusive events in patients with ischemic stroke // JAMA. — 2004. — Vol. 291. — Р. 576–584. - Tektonidou M. G., Laskari K., Panagiotakos D. B., Moutsopoulos
H. M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies // Arthritis Rheum. — 2009. — Vol. 61, № 1. — Р. 29–36. - Erkan D., Yazici Y., Peterson M. G. et al. A
cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome // Rheumatology (Oxford). — 2002. — Vol. 41. — Р. 924–929. - Ruffatti A., Del Ross T., Ciprian M. et al. Risk factors for a fi rst thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective
follow-up study // Ann. Rheum. Dis. — 2009. — Vol. 68, № 3. — Р. 397–399. - Kaiser R., Cleveland C., Criswell
L. A. Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large,multi-ethnic cohort // Ann. Rheum. Dis. — 2009. — Vol. 68, № 2. — Р. 238–241. - Pengo
v. , Ruffatti A., Legnani C. et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profi le: a multicenter prospective study // Blood. — 2011. — Vol. 118, № 17. — Р. 4714–4718. - Tektonidou M. G., Ioannidis J. P.A, Boki K. A. et al. Prognostic factors and clustering of serious clinical outcomes in antiphospholipid syndrome //
Q. J. Med . — 2000. — Vol. 93, № 8. — Р. 523–530. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C. et al. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals // J. Rheumatol. — 2004. — Vol. 31, № 8. — Р. 1560–1567.- Urbanus R. T., Siegerink B., Roest M. et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a
case-control study // Lancet Neurol. — 2009. — Vol. 8, № 11. — Р. 998–1005. - Mehdi A. А., Uthman I., Khamashna M. Treatment of antiphospholipid syndrome // Int. J. Clin. Rheumatol. — 2010. — Vol. 5, № 2. — Р. 241–254.
- Lassere M., Empson M. Treatment of antiphospholipid syndrome in pregnancy — a systemic review of randomized therapeutic trials // Thromb. Res. — 2004. — Vol. 114, № 5–6. — Р. 419–426.
- Tincani A., Lojacono A., Taglietti M. et al. Pregnancy and neonatal outcome in primary antiphospholipid syndrome // Lupus. — 2002. — Vol. 11, № 10. — Р. 649–655.
- Ginnakopoulos B., Krilis
S. A. Haw I treat the antiphospholipid syndrome // Blood. — 2009. — Vol. 114, № 10. — Р. 2020–2030. - Tutill J. L., Khamashta
M. A. Management of antiphospholipid syndrome // J. Autoimmun. — 2009. — Vol. 33, № 2. — Р. 92–98. - Chan A. T., Manson J. E., Feskanich D. et al. Long term aspirin use and mortality in women // Arch. Int. Med. — 2007. — Vol. 167, № 6. — Р. 562–572.
- Erkan D., Harrison M. J., Levy R. et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized,
double-blind ,placebo-controlled trial in asymptomatic antiphospholipidantibody-positive individuals // Arthritis Rheum. — 2007. — Vol. 56. — Р. 2382–2391. - Bertsias G., Ioannidis J. P.A., Boletis J. et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics // Ann. Rheum. Dis. — 2008. — Vol. 67. — Р. 195–205.
- Clark P., Walker I. D., Langhorne P. et al. SPIN (Scottish Pregnancy Intervention) study: a multicenter, randomized controlled trial of
low-molecular-weight heparin andlow-dose aspirin in women with recurrent miscarriage // Blood. — 2010. — Vol. 115, № 21. — Р. 4162–4167. - Empson M., Lasser M., Craig G., Scott J. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant // Cochran Database Syst. Rev. (2) — 2005. — Vol. 18, № 2. — CD002859 (doi: 10.1002/14651858.cd002859.pub2).
- Noble L. S., Kutteh W. H., Lashey N. et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with
low-molecular-weight heparin versus unfractionated heparin // Fertil. Steril. — 2005. — Vol. 83, № 3. — Р. 684–690. - Stephenson M. D., Ballem P. J., Tsang P. et al. Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin // J. Obstet. Gynecol. Can. — 2004. — Vol. 26, № 8. — Р. 729–734.
- Locke J. E., Magro C. M., Singer A. L. et al. The use of antibody to complement protein C5 for salvage treatment of severe
antibody-mediated rejection // Am. J. Transplant. — 2009. — Vol. 9, № 1. — Р. 231–235. - Lonze B. E., Singer A. L., Montgomery
R. A. Eculizumab and renal transplantation in a patient with CAPS // N. Engl. J. Med. — 2010. — Vol. 362, № 18. — Р. 1744–1745. - Erkan D., Lockshin
M. D. New approaches for managing antiphospholipid syndrome // Nat. Clin. Pract. Rheumatol. — 2009. — Vol. 5, № 3. — Р. 160–170. - Asherson R. A., Cervera R., de Groot P. R. et al. Catastrophic antiphospholipid syndrome: inter- national consensus statement on classification criteria and treatment guidelines // Lupus. — 2003. — Vol. 12, № 7. — Р. 530–534.
- Bucciarelli S., Cervera R., Espinosa G. et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors // Autoimmun. Rev. — 2006. — Vol. 6, № 2. — Р. 72–75.
- Kitchens C. S., Erkan D., Brandão L. R. et al. Thrombotic storm revisited: preliminary diagnostic criteria suggested by the Thrombotic Storm Study Group // Am. J. Med. — 2011. — Vol. 124, № 4. — Р. 290–296.
- Erkan D., Espinosa G., Cervera R. Catastrophic antiphospholipid syndrome: updated diagnostic algorithms // Autoimmun. Rev. — 2010. — Vol. 10, № 2. — Р. 74–79.
- Asherson R. A., Cervera R. Microvascular and microangiopathic
antiphospholipid-associated syndromes («MAPS»): semantic or antisemantic? // Autoimmun. Rev. — 2008. — Vol. 7. — Р. 164–167. - Espinosa G., Cervera R. Antiphospholipid syndrome: frequency, main causes and risk factors of mortality // Nat. Rev. Rheumatol. — 2010. — Vol. 6, № 5. — Р. 296–300.
- Erkan D., Leibowitz E., Berman J., Lockshin
M. D. Perioperative medical management of antiphospholipid syndrome: hospital for special surgery experience, review of literature, and recommendations // J. Rheumatol. — 2002. — Vol. 29, № 4. — Р. 843–849. - Cervera R., Tektonidou M. G., Espinosa G. et al. Task force on catastrophic antiphospholipid syndrome (APS) and
non-criteria APS manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions // Lupus. — 2011. — Vol. 20. — Р. 165–173. - Cervera R., Bucciarelli S., Plasín M. A. et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the «CAPS Registry» // J. Autoimmun. — 2009. — Vol. 32, № 3–4. — Р. 240–245.
- Szczepiorkowski Z. M., Winters J. L., Bandarenko N. et al. Guidelines on the use of therapeutic apheresis in clinical practice —
evidence-based approach from the apheresis applications committee of the American Society for Apheresis // J. Clin. Apher. — 2010. — Vol. 25, № 3. — Р. 83–177. - Erkan D. Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome // Autoimmun. Rev. — 2006. — Vol. 6. — Р. 98–103.
- Scobe T., Wijetillea S., Khamashta
M. A. Management of refractory antiphospholipd syndrome // Autoimmun. Rev. — 2011 (doi:10.1016/j.autrev. 2011.04.030). - Xarelto 10 mg
film-coated tablets. Summary of product characteristics (SPC), EU. Bayer HealthCare AG. Date of fi rst authorisation/renewal of authorisation: 30/09/08. Date of revision 12/2011. — Available at: www.emc.medicines.org.uk. - Lee C. J., Ansell
J. E. Direct thrombin inhibitors // Br. J. Clin. Pharmacol. — 2011. — Vol. 72, № 4. — Р. 581–592. Gomez-Outes A.,Terleira-Fernandez A.I.,Calvo-Rojas G. et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systemic review andmeta-analysis of subgroups // Thrombosis. — 2013. — Vol. 2013. — Article ID640723 (doi: 10.1155/2013/640723).- Eriksson B. I., Quinlan D. J., Eikelboom
J. W. Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism // Annu. Rev. Med. — 2011. — Vol. 62, № 1. — Р. 41–57 (doi: 10.1146/annurevmed-062209-095159 ). - Bick R. L., Rice J.
Long-term outpatients dalteparin (fragmin) therapy for arterial and venous thrombosis: efficacy and safety — a preliminary report // Clin. Appl. Thromb. Hemost. — 1999. — Vol. 5 (Suppl 1). —S67-S71 . - Montoya R. C., Gajra A. Current status of new anticoagulants in the management of venous thromboembolism // Advances in Hematol. — 2012. — Article ID856341 (doi: 10,1155/2012/856341).
Ключевые слова
тромбофилия, антифосфолипидный синдром, антифосфолипидные антитела, системная красная волчанка